The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.
Umberto Vitolo, MD
Advertisement
Umberto Vitolo, MD, is a consultant hematologist and head of hematology clinical trials at Candiolo Cancer Institute.
Articles by Umberto Vitolo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
3
Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox
4
Incretin Innovation, Metabolic Liver Disease, and Cardiovascular Risk Reduction Dominate ADA 2026
5